A new cost-saving in vivo shuttle session on validated syngeneic mouse tumor models

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?

Explicyte is indeed planning a new in vivo shuttle session by mid-October, to be held on a series of syngeneic tumor-bearing mouse models such as MCA025 sarcoma, 4T1 & EMT6 breast cancer, MC38 & CT26 colon cancer or Renca renal cancer, among others. These models can be run either for only efficacy monitoring or for a comprehensive assessment based on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.

For this shuttle session, you can register HERE and get your study scheduled in October.

MCA205 sarcoma, MC38 colon and CT26 colon tumor-bearing mouse models exhibit various tumor growth profiles and differential responsiveness to PDL1 blockade.

Figure 1. MCA205 sarcoma, MC38 colon and CT26 colon tumor-bearing mouse models exhibit various tumor growth profiles and differential responsiveness to PDL1 blockade.
Mice were challenged with respective tumor cells and exposed to vehicle or anti-PDL1 antibody. Tumor growth was then monitored overtime. The three tumor models represented display differential response to PDL1 blockade - MCA205 and MC38 tumors being responsive while CT26 model is only partially sensitive.

. PDL1 blockade effect and mechanism of action in the subcutaneously-implanted MC38 colon tumor-bearing mouse model.

Figure 2. PDL1 blockade effect and mechanism of action in the subcutaneously-implanted MC38 colon tumor-bearing mouse model.
A. Mice were subcutaneously implanted with MC38 colon tumor cells, exposed to anti-PDL1 antibody. Tumor growth was monitored overtime (see Figure 1) and survival was determined. PDL1 blockade induces an improvement in survival, compared to control (vehicle treated) (p value<0,0005) – an effect likely underpinned by the modulation of the immune tumor infiltrate.
B. Flow cytometry analysis of MC38 tumors shows infiltration by both lymphocytic (CD4, CD8) and myeloid cells – CD11b/F4:80 macrophages, including M1 and M2 subsets. Upon anti-PDL1 treatment, an increase in CD8 cytotoxic lymphocytes and a decrease of myeloid CD11b/F4:80 cell infiltration were observed. In addition, while vehicle tumors were shown to be infiltrated by M2 macrophages, which helps conferring an immunosuppressive microenvironment, PDL1 blockade was demonstrated to reprogram this macrophage profile by increasing the M1 and decreasing the M2 subset proportions, thereby suggesting an effect on macrophage polarization and proliferation.